Movement Alert|WuXi Biologics Rises 3.24% in Regular Trading, Star Fund Manager Zhao Feng Adds Stock as New Top-10 Holding

Market Focus
07/20

On July 20, WuXi Biologics rose 3.24% in regular trading, trading at 38.66 HKD/share, with turnover of approximately 202 million HKD.

On the news front, Ruiyuan Fund's prominent fund manager Zhao Feng disclosed in the Q2 report of his Ruiyuan Balanced Value Three-Year Holding Fund that WuXi Biologics has newly entered the fund's top-10 holdings, with a position weight of approximately 4.34%. This marks Zhao's return to the stock after a one-year absence, sending a strong institutional confidence signal to the market.

The broader Life Sciences Tools and Services sector rallied in tandem, with Joinn Laboratories up 7.24%, Pharmaron up 5.69%, WuXi XDC up 4.13%, Insilico Medicine up 4.12%, and WuXi AppTec up 2.48%. The stock had previously dropped 5.95% on July 17 amid sector-wide weakness, and the combination of the star fund manager's endorsement and sector recovery triggered a technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10